Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia

Heart and Vessels

Volumn 30, Issue 4, 2015, Pages 503-509

  Zhou, Yuheng ^a   Niu, Jianmin ^a   Duan, Dongmei ^a   Lei, Qiong ^a   Wen, Jiying ^a   Lin, Xiaohong ^a   Lv, Lijuan ^a   Chen, Longding ^a  

^a Guangdong Women and Children's Hospital   (China)

Author keywords

Dyslipidemia; Hypertension; Lp PLA2; Preeclampsia; Vascular inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FAMILY HISTORY; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PARITY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; COMPLICATION; DYSLIPIDEMIA; HYPERTENSION; PUERPERIUM; STATISTICAL MODEL; YOUNG ADULT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; BIOMARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; DYSLIPIDEMIAS; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION; LOGISTIC MODELS; POSTPARTUM PERIOD; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; ROC CURVE; YOUNG ADULT;

EID: 84938422791     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-014-0514-7     Document Type: Article

References (36)

1. World Health Organization (2012) World Health Statistics. www.who.int/gho/publications/world_health_statistics/2012/en/
2. Saito T, Mochizuki T, Uchida K, Tsuchiya K, Nitta K (2013) Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan. Heart Vessels 28:323–329
3. Craici I, Wagner S, Garovic VD (2008) Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis 2(4):249–259
4. Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, Gokhale M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sørensen HT, Walker R, Weir CJ (2011) Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. BMJ Open 1(1):e000101
5. Bellamy L, Casas JP, Hingorani AD, Williams DJ (2007) Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335:974–985
6. Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH (1996) Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 16(4):591–599
7. Lavi S, Herrmann J, Lavi R, McConnell JP, Lerman LO, Lerman A (2008) Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Curr Atheroscler Rep 10(3):230–235
8. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A (2007) Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115(21):2715–2721
9. Vickers KC, Maguire CT, Wolfert R, Burns AR, Reardon M, Geis R, Holvoet P, Morrisett JD (2009) Relationship of lipoprotein-associated phospholipase A 2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res 50:1735–1743
10. Zalewski A, Macphee C (2005) Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25(5):923–931
11. ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33. Int J Gynaecol Obstet 77(1):67–75
12. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development Group (2011) Management of hypertension: summary of NICE guidance. BMJ 343:d4891
13. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB (2005) Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26(2):137–144
14. Clausen T, Djurovic S, Henriksen T (2001) Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia. BJOG 108(10):1081–1087
15. Adams MR, Kinlay S, Blake GJ, Orford JL, Ganz P, Selwyn AP (2000) Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic syndromes. Annu Rev Med 51:149–167
16. Dekker GA, Sibai BM (1998) Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 179(5):1359–1375
17. Russell R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126
18. Adiga U, D’souza V, Kamath A, Mangalore N (2007) Antioxidant activity and lipid peroxidation in preeclampsia. J Chin Med Assoc 70(10):435–438
19. Sesso HD, Buring JE, Chown MJ, Ridker PM, Gaziano JM (2005) A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med 165(20):2420–2427
20. Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Michael Gaziano J (2006) Dyslipidemia and the risk of incident hypertension in men. Hypertension 47(1):45–50
21. de Simone G, Devereux RB, Chinali M, Roman MJ, Best LG, Welty TK, Lee ET, Howard BV, Strong Heart Study Investigators (2006) Risk factors for arterial hypertension in adults with initial optimal blood pressure: the strong heart study. Hypertension 47(2):162–167
22. Laaksonen DE, Niskanen L, Nyyssonen K, Lakka TA, Laukkanen JA, Salonen JT (2008) Dyslipidaemia as a predictor of hypertension in middle-aged men. Eur Heart J 29(20):2561–2568
23. Vaziri ND, Rodríguez-Iturbe B (2006) Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2(10):582–593
24. Niskanen L, Laaksonen DE, Nyyssönen K, Punnonen K, Valkonen VP, Fuentes R, Tuomainen TP, Salonen R, Salonen JT (2004) Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 44(6):859–865
25. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM (2003) C-reactive protein and the risk of developing hypertension. JAMA 290(22):2945–2951
26. Engström G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, Lindgärde F (2002) Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 22(12):2054–2058
27. Spaan JJ, Sep SJ, van Balen VL, Spaanderman ME, Peeters LL (2012) Metabolic syndrome as a risk factor for hypertension after preeclampsia. Obstet Gynecol 120(2 Pt 1):311–317
28. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A (2007) Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115(21):2715–2721
29. Kotchen JM, McKean HE, Kotchen TA (1982) Blood pressure of young mothers and their children after hypertension in adolescent pregnancy: six-to nine-year follow-up. Am J Epidemiol 115(6):861–867
30. Taguchi E, Nishigami K, Miyamoto S, Sakamoto T, Nakao K (2014) Impact of shear stress and atherosclerosis on entrance-tear formation in patients with acute aortic syndromes. Heart Vessels 29:78–82
31. Nguyen TT, Adair LS, He K, Popkin BM (2008) Optimal cutoff values for overweight: using body mass index to predict incidence of hypertension in 18- to 65-year-old Chinese adults. J Nutr 138(7):1377–1382
32. Kuklinska AM, Mroczko B, Musial WJ, Usowicz-Szarynska M, Sawicki R, Borowska H, Knapp M, Szmitkowski M (2009) Diagnostic biomarkers of essential arterial hypertension: the value of prostacyclin, nitric oxide, oxidized-LDL, and peroxide measurements. Int Heart J 50(3):341–351
33. Kajiya M, Miyoshi T, Doi M, Usui S, Iwamoto M, Takeda K, Nosaka K, Nakayama R, Hirohata S, Kusachi S, Nakamura K, Ito H (2013) Serum adipocyte fatty acid-binding protein is independently associated with complex coronary lesions in patients with stable coronary artery disease. Heart Vessels 28:696–703
34. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D’Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American heart association. Circulation 123(11):1243–1262
35. Tobaru T, Seki A, Asano R, Sumiyoshi T, Hagiwara N (2013) Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease. Heart Vessels 28:39–45
36. Tsimihodimos V, Tselepis AD (2010) Effect of cardiovascular drugs on the plasma levels of lipoprotein associated phospholipase A2 (Lp-PLA2). Open Clin Chemi J 3:60–65